3B Pharmaceuticals GmbH

3B Pharmaceuticals GmbH, commonly known as 3BP, is a privately held German biotechnology company headquartered in Berlin. Founded in 2008, the company focuses on the discovery and development of peptide-based radiopharmaceuticals, particularly for targeted radioligand therapy and molecular imaging in oncology. 3BP's core expertise lies in peptide chemistry, radiolabeling, and the design of novel targeting vectors that bind to cancer-specific receptors. The company has built a pipeline of proprietary compounds and also collaborates with pharmaceutical partners to develop radiopharmaceutical candidates. Its work is positioned at the intersection of nuclear medicine and precision oncology, a field that has attracted significant investment and deal-making in recent years. As a private company, 3BP does not disclose detailed financial information publicly, and its ownership structure is not widely reported. The company operates primarily in Germany and Europe, with partnerships extending to international markets. Its research and development activities are centered on improving the efficacy and safety of radioligand therapies, including the use of alpha and beta emitters. 3BP's scientific team has published research in peer-reviewed journals and presented at industry conferences, contributing to the advancement of the radiopharmaceutical field. The company remains an active player in the growing radiopharmaceutical sector, though specific product approvals and commercial launches are not publicly documented in the available evidence.

3B Pharmaceuticals GmbH (3BP) was founded in 2008 in Berlin, Germany, as a biotechnology company focused on peptide-based radiopharmaceuticals. The company emerged in a period when targeted radioligand therapy was gaining traction as a promising approach in oncology, particularly following the success of peptide receptor radionuclide therapy (PRRT) for neuroendocrine tumors. 3BP built its expertise around the design and synthesis of peptides that can be labeled with radioactive isotopes for both therapy and imaging. Over the years, the company has engaged in research collaborations with academic institutions and industry partners to advance its pipeline. While specific milestones such as financing rounds, partnerships, or clinical trial initiations are not detailed in the available evidence, 3BP has maintained an active presence in the radiopharmaceutical research community. The company's work aligns with the broader growth of the radiopharmaceutical sector, which has seen increased investment and deal activity in the 2010s and 2020s. As a private entity, 3BP's corporate developments are not widely publicized, and its history is primarily reflected through scientific publications and conference presentations. The company remains headquartered in Berlin and continues to focus on its core mission of developing innovative radiopharmaceuticals for cancer treatment and diagnosis.

• 2008

  3B Pharmaceuticals GmbH founded in Berlin, Germany.

3BP positions itself as a specialized radiopharmaceutical company focused on peptide-based targeting vectors for precision oncology, bridging nuclear medicine and drug development.

• Peptide-based radiopharmaceuticals

  Targeting vectors labeled with radioisotopes for therapy and imaging.

1. 1Clovis Oncology acquires rights to FAP-targeted radiopharmaceutical programme from 3B Pharmaceuticals - Pharmaceutical Business reviewpharmaceutical-business-review.com